Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 302 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer of Pelvis Clear all

Conditions: Abdominal Cancer, Pelvic Cancer
Interventions: Cardiopulmonary Exercise Testing (CPET); Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Epithelial Ovarian Cancer
Interventions: DNA Methylation; Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Malignancies, Stenosis of Vagina
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Bladder Cancer, Cervical Cancer, Endometrial Cancer, Vaginal Cancer
Interventions: paclitaxel, vinorelbine tartrate, radiation therapy; Drug · Radiation
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2001
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma
Interventions: Conventional Surgery; Procedure
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 38
States / cities: Birmingham, Alabama • Aurora, Colorado • Hartford, Connecticut + 28 more

Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions: gemcitabine hydrochloride, pemetrexed disodium; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 121
States / cities: Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 88 more

Conditions: Abdominal Malignancy, Pelvic Malignancy
Interventions: CivaSheet, Brachytherapy, surgical resection; Device · Radiation · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions: gemcitabine hydrochloride, paclitaxel; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 16
States / cities: Cedar Rapids, Iowa • Kalamazoo, Michigan • East Orange, New Jersey + 10 more

Conditions: Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0a Renal Pelvis Cancer AJCC v8, Stage 0a Ureter Cancer AJCC v8, Stage 0a Urethral Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage 0is Renal Pelvis Cancer AJCC v8, Stage 0is Ureter Cancer AJCC v8, Stage 0is Urethral Cancer AJCC v8, Stage II Bladder Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8, Stage II Ureter Cancer AJCC v8, Stage II Urethral Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions: Erlotinib Hydrochloride; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Childhood Malignant Solid Neoplasm, Childhood Malignant Thoracic Neoplasm, Malignant Abdominal Neoplasm, Malignant Neck Neoplasm, Malignant Pelvic Neoplasm, Metastatic Childhood Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Near Infrared Imaging, Pafolacianine Sodium, Surgical Procedure; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 6 Months to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Bone Sarcoma, Chondrosarcoma, Chordoma, Ewing Sarcoma of Bone, Pelvic Rhabdomyosarcoma
Interventions: Electronic Health Record Review, Quality-of-Life Assessment; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 15 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Thymoma, Mediastinal Tumor, Gynecologic Disease, Gynecologic Cancer, Pelvic Organ Prolapse, Prostate Disease, Prostate Cancer, Inguinal Hernia, Ventral Hernia, Obesity, Morbid
Interventions: Robotic-assisted Surgery; Device
Lead sponsor: Intuitive Surgical; Industry
Eligibility: 21 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 4
States / cities: Orlando, Florida • Lansing, Michigan • Ridgewood, New Jersey + 1 more

Conditions: Cancer
Interventions: entinostat; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 3
States / cities: Bethesda, Maryland

Conditions: Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions: indocyanine green solution, diffuse optical imaging, robot-assisted laparoscopic surgery, therapeutic lymphadenectomy; Drug · Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Duarte, California

Conditions: Solid Cancers, Solid Tumor Cancer, Solid Tumor Malignancy, Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer), Metastatic Solid Tumor, Locally Advanced Solid Tumor, Urothelial Cancer of Renal Pelvis
Interventions: XL495, ADC cytotoxic agents; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 10
States / cities: Denver, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more

Conditions: Diverticulum, Colon, Colorectal Neoplasms, Crohn Disease, Colitis, Ulcerative, Colostomy, Ileostomy - Stoma, Rectal Prolapse, Intestinal Polyposis, Lymphoma, Endometriosis, Intestinal Volvulus
Interventions: ColonRing™; Device
Lead sponsor: novoGI; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Riverdale, Georgia

Conditions: Metastatic or Recurrent Lesions in the Spine, Metastatic or Recurrent Lesions in the Pelvis
Interventions: Ir-192 high dose rate (HDR); Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Fatigue, Neurotoxicity Syndrome, Obesity, Stage I Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7
Interventions: 3-Dimensional Conformal Radiation Therapy, Carboplatin, Intensity-Modulated Radiation Therapy, Internal Radiation Therapy, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration; Radiation · Drug · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 533
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 352 more

Conditions: Urothelial Carcinoma
Interventions: Avelumab, AVB-S6-500; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Endometrial Cancer
Interventions: Hypofractionated WPRT; Radiation
Lead sponsor: Teresa Meier; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Head and Neck Cancer, Thoracic Cancer, Abdominal Cancer, Pelvic Cancer
Interventions: HyperSight imaging; Device
Lead sponsor: Varian, a Siemens Healthineers Company; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
Interventions: Gemcitabine hydrochloride, Paclitaxel, Doxorubicin hydrochloride, Pegfilgrastim; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 2
States / cities: Springfield, Missouri • Houston, Texas

Conditions: Anal Carcinoma, Cervical Carcinoma, Endometrial Carcinoma, Malignant Pelvic Neoplasm, Rectal Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma
Interventions: Pelvic Examination, Survey; Procedure · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Prostate Cancer
Interventions: [68Ga]-LNTH-2401; Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Search by objective public record fields.

A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer

Longitudinal Evaluation Study of Vaginal Stenosis With and Without Pelvic Radiation Therapy

Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis

Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer

Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

Intraoperative Radiation Therapy for Locally Advanced or Recurrent Abdomino-pelvic Solid Tumors With the CivaSheet

Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors

Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone

Clinical Investigation of the da Vinci Surgical System

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Diffuse Optical Imaging With Indocyanine Green Solution in Imaging Pelvic Lymph Nodes in Patients With Stage II Prostate Cancer Undergoing Surgery

A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors

Data Collection of Patients Treated With the ColonRing™ for the Creation of Circular Compression Anastomosis

Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine and Pelvis

Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma

Adjuvant Hypofractionated Whole Pelvis Radiation Therapy in Endometrial Cancer

A Prospective Imaging Study of the Integrated TrueBeam-HyperSight CBCT System

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy

Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])